Table 4.
Comparision of Radiologic and Pulmonary function features between MPO-ANCA-IIP and non-MPO-ANCA-IIP
| Characteristic | MPO-ANCA-IIP(n = 25) | Non-MPO-ANCA-IIP(n = 36) | P -value |
|---|---|---|---|
| HRCT Abnormalities | |||
| Ground-glass opacity | 22 (88.0) | 33 (91.7) | 0.682 |
| Traction bronchiectasis | 11 (44.0) | 10 (27.8) | 0.190 |
| Honeycombing | 5 (20.0) | 5 (13.9) | 0.526 |
| Reticular pattern | 16 (64.0) | 20 (55.6) | 0.510 |
| Fibrosisa | 13 (52.0) | 9 (22.0) | 0.031 |
| HRCT patterns | |||
| UIP | 5 (20.0) | 4 (11.1) | 0.336 |
| Non-UIP | |||
| NSIP | 13 (52.0) | 23 (63.9) | 0.353 |
| OP | 0 (0.0) | 1 (2.8) | 1.000 |
| NSIP with OP overlap | 0 (0.0) | 0 (0.0) | 1.000 |
| Unclassifiable | 7 (28.0) | 8 (22.2) | 0.606 |
| Pulmonary function tests | |||
| Baseline FEV1, % predicted | 87.40 (77.80,95.00) | 75.75 (66.23,89.15) | 0.034 |
| Baseline FVC, % predicted | 84.40 (71.80,92.60) | 77.10 (61.83,96.30) | 0.276 |
| Baseline TLC, % predicted | 80.10 (66.25,87.20) | 73.10 (64.30,82.03) | 0.267 |
| Baseline DLCO, % predicted | 62.10 (57.30,76.65) | 55.55 (44.33,67.75) | 0.098 |
| ΔFEV1, % predicted b | −5.43 ± 6.41 | 2.02 ± 8.96 | 0.016 |
| ΔFVC, % predicted b | −6.71 ± 8.79 | 4.09 ± 10.33 | 0.004 |
| ΔTLC, % predicted b | −6.13 ± 9.44 | 3.57 ± 10.42 | 0.020 |
| ΔDLCO, % predicted b | −8.77 ± 12.07 | 3.24 ± 9.70 | 0.005 |
| Pulmonary function progression b | 7 (58.3) | 4 (18.2) | 0.026 |
| Pulmonary function stable b | 5 (41.7) | 14 (63.6) | 0.218 |
| Pulmonary function improvement b | 0 (0) | 4 (18.2) | 0.273 |
| Treatment | |||
| Corticosteroids | 22 (88.0) | 30 (83.3) | 0.725 |
| Medium dose | 8 (32.0) | 9 (25.0) | 0.549 |
| High dose | 13 (52.0) | 21 (58.3) | 0.624 |
| Cyclophosphamide | 6 (24.0) | 8 (22.2) | 0.871 |
| Other immunosuppressants c | 2 (8.0) | 1 (2.8) | 0.562 |
| Anti-fibrosis d | 3 (12.0) | 3 (8.3) | 0.682 |
| None e | 3 (12.1) | 7 (19.4) | 0.727 |
| Death of all cause | 6 (24.0) | 5 (13.9) | 0.747 |
Data are presented as the medians (IQRs), means ± SDs or No. (%)
MPO myeloperoxidase, ANCA anti-neutrophil cytoplasmic antibody, IIP idiopathic interstitial pneumonia, HRCT high resolution computed tomography, UIP usual interstitial pneumonia, NSIP nonspecific interstitial pneumonia, OP organizing pneumonia, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, TLC total lung capacity, DLCO diffusing capacity of lung for carbon monoxide
aFibrosis was radiologically defined as the presence of honeycombing and traction bronchiectasis; honeycombing and reticular patterns; or traction bronchiectasis and reticular patterns
bMPO-ANCA-IIP: n = 12; Non-MPO-ANCA-IIP: n = 22
cOther immunosuppressants include tacrolimus, azathioprine, mycophenolate mofetil, methotrexate, hydroxychloroquine, and tripterygium wilfordii
dAnti-fibrosis include nintedanib and pirfenidone
eNone represents not receiving anti-inflammatory and anti-fibrotic therapy